Pfizer-Allergan deal a prelude to splitting company
(Reuters) — A Pfizer (NYSE:PFE) merger with Ireland-based Allergan (NYSE: AGN), in addition to providing tax benefits, would bolster the U.S. drugmaker’s growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent. Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling 3 years of financial data treating its “established products” division, which sells generic medicines, and its “innovative” patent-protected medicines unit, as if they were separate companies. Such a split would dramatically boost the compan...
Source: Mass Device - November 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Pharmaceuticals Allergan Inc. Pfizer Inc. Source Type: news
Heart Disease and Diabetes Trials Anticipated at Kidney WeekHeart Disease and Diabetes Trials Anticipated at Kidney Week
New data will be presented on empagliflozin in patients with diabetes, and results from trials of atorvastatin and kidney injury after cardiac surgery will be released. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 29, 2015 Category: Consumer Health News Tags: Nephrology News Source Type: news
Impact of Dual Lipid-Lowering on Coronary PlaqueImpact of Dual Lipid-Lowering on Coronary Plaque
Find out how ezetimibe and atorvastatin combined impact coronary atherosclerosis in patients undergoing PCI. Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2015 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Dr Reddy's recalls over 55K bottles of hypertension drug in US
Dr Reddy's Laboratories is recalling over 55,000 bottles of Amlodipine besylate and Atorvastatin calcium tablets. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 4, 2015 Category: Pharmaceuticals Source Type: news
FTC clears Pfizer’s $15B Hospira buy
Pfizer (NYSE:PFE) said Monday it won approval from the Federal Trade Commission for its $15 billion acquisition of Hospira (NYSE:HSP). The clearance came with a caveat –Pfizer must divest itself of its Acetylcysteine, Clindamycin, Voriconazole and Melphalan sterile injectable assets, according to the company. The news from the FTC came August 21, according to an SEC filing from Hospira, and leaves the company with only 1 post-clearance waiting period in a single foreign jurisdiction, though the region was not specified. Pfizer also announced that Brazil has given the merger the thumbs up. “We are pleased to have...
Source: Mass Device - August 27, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Hospira Inc. Pfizer Inc. Source Type: news
Pfizer wins Canadian approval for $15B Hospira buy
Pfizer (NYSE:PFE) said it won approval from the Canadian Competition Bureau for its $15 billion acquisition of Hospira (NYSE:HSP). As part of the agreement, the healthcare and pharmaceutical giant said it committed to divesting certain assets of the company in Canada, according to a press release. “We are pleased the Canadian Competition Bureau concluded its review of the transaction and approved the pending combination of Pfizer and Hospira. We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close in the second half of 2015,...
Source: Mass Device - August 14, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Hospira Inc. Pfizer Inc. Source Type: news
Pfizer Pulls The Plug On OTC Lipitor And It's The Patients' Fault
However, my guess is that payers will be disappointed by these results as they do not usually cover OTC medications and, despite the fact most statins are now generic, these drugs still impact their bottom-line. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 29, 2015 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Hand-Foot Syndrome Prevention With Atorvastatin, PolyprenolHand-Foot Syndrome Prevention With Atorvastatin, Polyprenol
Breast cancer patients receiving capecitabine had a lower incidence of hand-foot syndrome after prophylactic treatment with atorvastatin and polyprenol. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 23, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association. For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news
Studies: Millions Could Benefit By Taking Cholesterol-Lowering Medications
BOSTON (CBS) — Millions more Americans could benefit from treatment with popular cholesterol-lowering medications, according to two new studies. Nearly half of adults ages 40-to-75 might be eligible to take them. Heart disease is still the number one killer of American men and women and cholesterol-lowering statins, like atorvastatin (Lipitor) and simvastatin (Zocor), have been shown to reduce heart disease in people at risk. Before, doctors would treat patients primarily based on their cholesterol levels, but a couple of years ago, leading cardiologists urged doctors to treat patients based on their overall risk inc...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 15, 2015 Category: Consumer Health News Authors: mouellette2015 Tags: Health Healthwatch Heart Health Local News Seen On WBZ-TV Syndicated Local Watch Listen Atorvastatin Dr. Mallika Marshall Health News Heart Disease Lipitor National Institutes Of Health Simvastatin Statins Zocor Source Type: news
Pfizer offers concessions to win EU okay for Hospira deal
(Reuters) — Pfizer (NYSE:PFE) offered concessions in a bid to win European Union regulatory approval for its $15 billion takeover of U.S. rival Hospira (NYSE:HSP), the European Commission said today. The EU competition authority did not provide details of Pfizer’s proposal, in line with its policy. It extended the deadline for its decision to Aug. 4 from July 20 to examine the concessions. It can either clear the deal, if it decides Pfizer has allayed competition concerns, or open a full-scale investigation. Pfizer, maker of impotence treatment Viagra and cholesterol drug Lipitor, is making its biggest-ever acqui...
Source: Mass Device - July 14, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Hospital Care Mergers & Acquisitions Hospira Inc. Pfizer Inc. Source Type: news
4 million more prescriptions for Atorvastatin since 2013, figures show
This makes it the drug with the highest rise in number of items dispensed over the past yearRelated items from OnMedicaGP prescribing has increased by almost 60 per cent in a decadeNorth of England tops league table for overall GP prescription costsStatins and dietary changes have saved 20,000 livesUS doctor says FDA should have withdrawn rosuvastatinGPs defend practice on prescribing statins (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 7, 2015 Category: UK Health Source Type: news
Lipitor Lawsuit News: Newly-Released Joint Status Report Indicates...
Bernstein Liebhard LLP is representing Lipitor lawsuit plaintiffs in the federal multidistrict litigation, and the discovery currently underway in this proceeding will allow access to information that...(PRWeb June 27, 2015)Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb12815681.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 29, 2015 Category: Pharmaceuticals Source Type: news
Statin Drugs and Prostate Cancer
Statin drugs are a group of widely prescribed ones used to lower a person's cholesterol level. Common statin medications include brands such as Lipitor, Crestor and Zocar. Statins work by inhibiting an enzyme in the human body, 'HMG-CoA reductase,' which is used to manufacture cholesterol and the drugs may also help to clear already formed cholesterol from the bloodstream. High cholesterol is a known cause of cardiovascular disease and it is well-established that statins reduce the rate of illness and death caused by cardiovascular disease. While statins can help to prevent the risk of a stroke or heart attack, some studie...
Source: Disabled World - June 8, 2015 Category: Disability Tags: Pharmaceutical - Drug Information Source Type: news
Federal Court Overseeing Hundreds of Lipitor Lawsuits Prepares to...
Bernstein Liebhard LLP is representing plaintiffs in federal Lipitor lawsuits, and anticipates that the upcoming conference will address issues relevant to those cases.(PRWeb June 06, 2015)Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb12772196.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 7, 2015 Category: Pharmaceuticals Source Type: news